Literature DB >> 17932963

Liposomes incorporating a Plasmodium amino acid sequence target heparan sulfate binding sites in liver.

Richard T Robertson1, Janie L Baratta, Sherry M Haynes, Kenneth J Longmuir.   

Abstract

Previous studies demonstrated that intravenously administered liposomes, incorporating a peptide from the Plasmodium circumsporozoite protein, accumulate rapidly and selectively in mouse liver. The present investigation was designed to determine the molecular components in liver responsible for liposome targeting. Studies of liver tissue slices demonstrated that immunoreactivity for heparan sulfate proteoglycan (HSPG), but not other tested proteoglycans, was distributed along sinusoidal borders of liver; this immunoreactivity appeared associated with nonparenchymal cells of the sinusoids and with the basolateral portion of hepatocytes. Peptide-containing liposomes bound to liver tissue in a pattern similar to the distribution of heparan sulfate immunoreactivity, either after intravenous injection of liposomes in vivo or after incubation of liposomes with liver slices in vitro. Control liposomes, without the peptide, displayed very light binding without a pattern. Pretreatment of liver slices with heparinase, but not chondroitinase or hyaluronidase, eliminated peptide-containing liposome binding, but did not affect binding of control liposomes. Coincubation of peptide-containing liposomes with heparin, but not with other glycosaminoglycans, markedly inhibited liposome binding to liver slices. N-desulfated and O-desulfated heparins individually were less effective inhibitors of liposome binding than was heparin. These results indicate that liposomes containing a peptide from Plasmodium target liver tissue by binding to HSPGs in the extracellular matrix.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 17932963     DOI: 10.1002/jps.21211

Source DB:  PubMed          Journal:  J Pharm Sci        ISSN: 0022-3549            Impact factor:   3.534


  10 in total

1.  Liposomal delivery of doxorubicin to hepatocytes in vivo by targeting heparan sulfate.

Authors:  Kenneth J Longmuir; Sherry M Haynes; Janie L Baratta; Natasha Kasabwalla; Richard T Robertson
Journal:  Int J Pharm       Date:  2009-08-05       Impact factor: 5.875

2.  Use of labeled tomato lectin for imaging vasculature structures.

Authors:  Richard T Robertson; Samantha T Levine; Sherry M Haynes; Paula Gutierrez; Janie L Baratta; Zhiqun Tan; Kenneth J Longmuir
Journal:  Histochem Cell Biol       Date:  2014-12-23       Impact factor: 4.304

3.  Cellular organization of normal mouse liver: a histological, quantitative immunocytochemical, and fine structural analysis.

Authors:  Janie L Baratta; Anthony Ngo; Bryan Lopez; Natasha Kasabwalla; Kenneth J Longmuir; Richard T Robertson
Journal:  Histochem Cell Biol       Date:  2009-03-03       Impact factor: 4.304

4.  Study of the efficacy of antimalarial drugs delivered inside targeted immunoliposomal nanovectors.

Authors:  Patricia Urbán; Joan Estelrich; Alberto Adeva; Alfred Cortés; Xavier Fernàndez-Busquets
Journal:  Nanoscale Res Lett       Date:  2011-12-07       Impact factor: 4.703

5.  Characterization of Kupffer cells in livers of developing mice.

Authors:  Bryan G Lopez; Monica S Tsai; Janie L Baratta; Kenneth J Longmuir; Richard T Robertson
Journal:  Comp Hepatol       Date:  2011-07-12

6.  Liver-targeted cyclosporine A-encapsulated poly (lactic-co-glycolic) acid nanoparticles inhibit hepatitis C virus replication.

Authors:  K R Jyothi; Jagadish Beloor; Ara Jo; Minh Nam Nguyen; Tae Gyu Choi; Jin-Hwan Kim; Salima Akter; Sang-Kyung Lee; Chi Hoon Maeng; Hyung Hwan Baik; Insug Kang; Joohun Ha; Sung Soo Kim
Journal:  Int J Nanomedicine       Date:  2015-01-30

Review 7.  Challenges of drug-resistant malaria.

Authors:  Shweta Sinha; Bikash Medhi; Rakesh Sehgal
Journal:  Parasite       Date:  2014-11-18       Impact factor: 3.000

8.  Protective efficacy of peptides from Plasmodium vivax circumsporozoite protein.

Authors:  Erwan Atcheson; Arturo Reyes-Sandoval
Journal:  Vaccine       Date:  2020-05-08       Impact factor: 3.641

9.  Antitumor activities of Liver-targeting peptide modified Recombinant human Endostatin in BALB/c-nu mice with Hepatocellular carcinoma.

Authors:  Ma Yan; Bao Dongmei; Zhang Jingjing; Jin Xiaobao; Wang Jie; Wang Yan; Zhu Jiayong
Journal:  Sci Rep       Date:  2017-10-26       Impact factor: 4.379

Review 10.  Liposomes for malaria management: the evolution from 1980 to 2020.

Authors:  Patrick B Memvanga; Christian I Nkanga
Journal:  Malar J       Date:  2021-07-27       Impact factor: 2.979

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.